13F Holdings
中文EN

VCEL Vericel Corp

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 887359 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY25.3%
TTM net income YoY154.6%
TTM EPS YoY146.2%
Revenue 3-yr CAGR20.5%
Net income 3-yr CAGR—

Margins

Gross margin74.5%
Operating margin8.3%
Net margin10.3%
FCF margin17.9%
EBITDA margin12.4%

Returns

ROE9.4%
ROA6.9%
ROIC (approx.)9.0%
Asset turnover0.67x

Leverage & solvency

Liabilities / assets25.7%
Debt / equity0.00x
Current ratio5.13x
Interest coverage42.01x

Cash quality & payout

Operating cash flow / net income1.96x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue2.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$85.37M$77.46M$68.42M$92.92M$67.50M$63.24M$52.60M$75.38M
Cost of revenue$22.76M$21.05M$19.16M$19.79M$17.92M$16.63M$16.32M$16.88M
Gross profit$62.61M$56.40M$49.27M$73.13M$49.59M$46.61M$36.27M$58.50M
R&D expense$6.88M$7.49M$8.10M$7.25M$6.32M$6.73M$7.26M$4.92M
SG&A expense$43.54M$48.48M$49.23M$43.46M$39.82M$41.91M$41.80M$35.10M
Operating income$12.19M$434,000-$8.06M$22.41M$3.45M-$2.03M-$12.79M$18.48M
Interest expense$160,000$160,000$160,000$162,000$158,000$157,000$153,000$154,000
Pretax income———————$19.95M
Income tax———————$148,000
Net income$14.16M$2.21M-$6.30M$23.24M$5.07M-$553,000-$11.25M$19.81M
EBITDA$15.69M$3.93M-$4.80M$25.50M$6.25M$671,000-$10.11M$19.96M
EPS (basic)0.280.04-0.12—0.10-0.01-0.23—
EPS (diluted)0.270.04-0.12—0.10-0.01-0.23—
Weighted avg. shares (diluted)52.96M52.31M50.77M—51.91M50.37M49.91M—
Balance sheet
Cash & equivalents$133.49M$125.36M$109.30M$100.09M$100.40M$80.53M$73.49M$85.05M
Short-term investments$36.77M$37.10M$36.05M$37.41M$34.98M$36.35M$39.41M$41.69M
Receivables$81.80M$75.71M$72.38M$84.63M$60.43M$64.29M$52.90M$61.38M
Inventory$17.06M$18.38M$18.35M$17.56M$18.16M$16.83M$17.11M$17.37M
Current assets$280.77M$264.73M$244.06M$247.44M$221.97M$204.58M$197.64M$212.78M
PP&E, net$105.08M$105.60M$107.11M$108.40M$109.38M$109.85M$108.29M$103.16M
Intangibles$5.16M$5.31M$5.47M$5.62M$5.78M$5.94M$6.09M$6.25M
Total assets$517.11M$502.87M$485.63M$487.97M$453.27M$435.61M$424.59M$432.72M
Current liabilities$54.72M$52.53M$47.16M$49.15M$45.58M$41.13M$39.45M$50.29M
Total liabilities$132.94M$132.82M$129.40M$133.33M$131.42M$128.80M$129.10M$140.75M
Shareholders' equity$384.17M$370.04M$356.23M$354.64M$321.86M$306.81M$295.49M$291.97M
Shares outstanding51.04M51.17M51.01M50.62M50.55M50.44M50.25M49.63M
Cash flow statement
Operating cash flow$17.72M$16.19M$16.38M$15.01M$22.08M$8.21M$6.60M$22.24M
Capital expenditure$2.04M$1.93M$1.26M$2.19M$2.63M$8.13M$14.21M$13.79M
Free cash flow$15.68M$14.26M$15.13M$12.83M$19.45M$81,000-$7.61M$8.46M
Investing cash flow-$2.71M-$2.82M-$4.20M-$16.39M-$3.38M-$9.03M-$15.14M-$14.65M
Financing cash flow-$6.88M$2.69M-$2.98M$1.06M$1.17M$1.64M$3.20M$7.11M
Depreciation & amortization$3.50M$3.50M$3.27M$3.09M$2.80M$2.70M$2.69M$1.48M
Stock-based compensation$7.82M$9.08M$11.29M$8.42M$8.70M$10.14M$11.51M$7.92M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.